Longevity & AgingOne CRISPR Shot Could Lower Bad Cholesterol for Years Without Permanent DNA Changes
A California biotech called Scribe Therapeutics has received regulatory clearance in Australia to begin the first human trial of STX-1150, a CRISPR-based therapy designed to lower LDL cholesterol long-term with just one dose. Rather than permanently rewriting DNA, it uses epigenetic silencing to suppress the PCSK9 gene in the liver — the same gene that, when naturally underactive, gives some people lifelong protection against heart disease. This approach could eventually replace decades of daily statins or repeat injections for high-risk patients. Cardiovascular disease kills more people globally than any other condition, and poor medication adherence is a major reason LDL targets go unmet. A durable, one-time treatment could close that gap significantly.
